Serena Di Cosimo: The prognostic value of residual tumor biology during neoadjuvant treatment in patients with HER2+ breast cancer
Serena Di Cosimo, Medical Director at IRCCS Foundation National Cancer Institute, Milan, shared a recent article on LinkedIn:
“This article published in Annals of Oncology explores the prognostic value of the biology of residual tumor disease and changes in gene expression during neoadjuvant treatment in patients with early HER2-positive breast cancer.
The results are the result of an international collaboration involving numerous researchers from all over the world.
I take this opportunity to publicly greet them all and to thank the Strategic Direction of the National Cancer Institute, the AIRC Foundation for Cancer Research and, above all, the women treated for HER2-positive breast cancer and their loved ones, who have made and make the research I am involved in possible.
I wish you all a Merry Christmas.”
Authors: Aranzazu Fernandez-Martinez, Maki Tanioka, Sung Gwe Ahn, Paola Zagami, Tomás Pascual, Mattia Rediti, Gong Tang, Katherine A. Hoadley, David Venet, Naim U. Rashid, Patricia A. Spears, Serena Di Cosimo, Evandro de Azambuja, Anup Choudhury, Priya Rastogi, Md N. Islam, Javier Cortes, Antonio Llombart-Cussac, Sandra M. Swain, Christos Sotiriou, Aleix Prat, Charles M. Perou and Lisa A. Carey
For more updates, follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023